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Prescription opioids have proven effective in
providing relief from many types of moderate
to severe pain.1---5 Opioid prescriptions in the
United States increased approximately 4-fold
from 1999 to 2010, largely as a result of
increased awareness of and efforts to address
untreated pain.6---8
Although this increase has been beneficial
for many patients, it has also contributed to
a dramatic rise in fatal and nonfatal opioid
overdose.9,10 Fatal poisonings, more than
90% of which are drug overdoses, have in-
creased nearly 6-fold in the past 3 decades
to become the country’s leading cause of
injury death.11 The rate of prescription
opioid-involved deaths now exceeds the rate
for heroin and cocaine combined.6,12 There
has also been a rapid increase in nonfatal
opioid overdose, with emergency department
visits involving nonmedical use of opioid
analgesics more than doubling between 2004
and 2008.13
Although increased prescription opioid
consumption is a key component of this rise,
prescription opioid overdose is a complex
phenomenon with a number of causal factors
at both the prescriber and patient level.14
Providers may prescribe opioids in amounts
or for durations or indications that are in-
consistent with evidence-based practice, and
patients may seek opioids from multiple pro-
viders because their pain is being inade-
quately managed or they have developed
addiction or dependence.15---17 Physician error,
patient nonadherence, physical health status,
poorly coordinated care, comorbidities such
as substance use disorders, and a number of
psychosocial factors also affect overdose
risk.14,18---21 Additionally, some unscrupulous
physicians have operated “pill mills” that pre-
scribe opioids in an indiscriminate and often
illegal manner.22,23
Prescription monitoring programs (PMPs) are
state-level databases that collect patient-specific
prescription information at the point of dis-
pensing. Data are generated and transmitted
to a central repository where, in most states,
authorized users such as medical professionals,
regulatory bodies, and law enforcement
agencies may access them.
In theory, PMPs could help address many of
the underlying causes of opioid overdose; they
may make physicians more aware of the
possible risks of prescribing a particular drug to
a particular patient, help to coordinate care
across providers, reduce overprescribing, assist
in identifying patients who might benefit from
screening for substance abuse treatment or
referral to a pain medicine specialist, and
permit law enforcement and regulatory
agencies to detect patients and prescribers who
may be engaging in illegal or unethical activi-
ties. Based on the assumption that PMPs can
reduce opioid overdose, their implementation
and utilization is recommended by the Centers
for Disease Control and Prevention, and mil-
lions of dollars of federal funds have been
earmarked to implement and upgrade
them.24,25 They are also a key component of
the President’s Prescription Drug Abuse Pre-
vention Plan, which sets the goal of decreasing
unintentional opioid overdose deaths by 15%
by 2016 and recommends that all states
operate PMPs and require prescribers to be
trained in their use.26
However, no published research has shown
a significant correlation between PMPs and
overdose, and there is little evidence of their
effect on other patient health outcomes. Exist-
ing research has largely evaluated the impact of
PMPs on outcomes such as “doctor shopping,”
prescribing practices, abuse and misuse, or
benefits to law enforcement.27---33 The only
published analysis examining the effect of
PMPs on overdose mortality found no signifi-
cant difference between states with PMPs and
those without them, although several limita-
tions of that study have been noted.34---36
Objectives. We sought to collect and characterize all laws governing the
operation of prescription monitoring programs (PMPs), state-level databases
that collect patient-specific prescription information, which have been sug-
gested as a tool for reducing prescription drug overdose fatalities.
Methods. We utilized a structured legal research protocol to systematically
identify, review, and code all PMP statutes and regulations effective from 1998
through 2011. These laws were then abstracted along eleven domains, including
reporting provisions, data sharing, and data access.
Results. PMP characteristics vary greatly among states and across time. We
observed an increase in the types and frequency of data required to be reported,
the types of individuals permitted to access PMP data, and the percentage of
PMPs authorized to proactively identify outlier prescribers and patients. As of
2011, 10 states required PMPs to report suspicious activity to law enforcement,
while only 3 required reporting to the patient’s physician. None required linkage
to drug treatment or required all prescribers to review PMP data before
prescribing. Few explicitly address data retention.
Conclusions. State PMP laws are heterogeneous and evolving. Future studies
of PMP effectiveness should take these variations into account. (Am J Public
Health. 2014;104:1389–1395. doi:10.2105/AJPH.2014.301923)
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This may be, in part, because nearly all
studies of PMP effectiveness have used a crude
binary measurement—whether the state had
a PMP—as their dependent variable. This ap-
proach assumes that all PMPs can be treated
homogenously regardless of their operational
characteristics. This is a nontrivial assumption,
which has been presented with little supporting
evidence. In fact, PMPs vary greatly in ways
that are likely to affect utilization and effec-
tiveness.37---40 There are wide variations be-
tween states and across time regarding such
basic programmatic elements as the types of
data required to be reported to the PMP, the
frequency with which data must be sent from
the dispenser to the central repository, who can
access the data and in what circumstances, and
where the PMP is administratively housed.
At the time previous studies were conducted,
no longitudinal database of the statutes and
regulations (hereafter referred to collectively as
“laws”) governing PMP operational character-
istics existed, making it extremely difficult to
factor these variations into research designs.
Using public health law research methods, we
have created the first in-depth, long-term lon-
gitudinal analysis of laws governing PMP op-
eration. This compendium covers relevant laws
from 1998 to 2011 across all 50 states, and
can inform future research.
METHODS
For each state, we first created a compilation
of laws relevant to PMP enactment, imple-
mentation, and operation that were in effect
between January 1, 1998, and December 31,
2011. TheWestlaw legal database was utilized
because it is accessible to most academic legal
researchers, provides a historical record of all
statutes and many regulations, and provides
tools that permit researchers to search for
existing relevant law, discover laws that cite to
identified laws, and view previous versions of
identified laws. Previous research has reported
no differences between the laws available on
Westlaw and LexisNexis, another popular legal
database.41
Identification of Laws
We began the research by identifying all
relevant PMP statues and regulations that were
in effect at the time the research was conducted
(February through July 2012) through several
methods. First, we searched each state’s stat-
utes and regulations using the string ((controlled
w/1 substance!) OR (prescription!) OR (drug!))
w/1 (report! OR monitor! OR database OR
repository). For statutes, we supplemented this
text search with an index search, in which we
searched each state’s statutory index for the
terms “prescription,” “electronic database,” and
“controlled substance.” All laws discovered
through this process were reviewed for rele-
vance by trained legal researchers using a ru-
bric developed by the authors.
When these searches yielded a relevant law,
the table of contents for the chapter containing
the relevant law was examined to determine if
any of the surrounding regulations or statutes
was also relevant. Additionally, Westlaw’s
“Citing References” function was utilized to
review all laws that referenced the relevant
laws. To minimize the possibility of missing
relevant statutes or regulations, 2 researchers
independently deployed this search scheme,
and any law that was deemed relevant by at
least 1 researcher was added to our database of
relevant laws. We also added to our final set of
relevant laws all statutes and regulations that
had been identified by the National Alliance for
Model State Drug Laws (NAMSDL), a nonprofit
organization that maintains a compendium of
PMP laws.42
In addition to identifying all current PMP
statutes and regulations, we utilized Westlaw’s
History function to identify and categorize
earlier versions of all laws deemed responsive
to the research questions. Where earlier ver-
sions were not available through Westlaw, we
utilized the Lexis database, the Hein database,
and state websites and law libraries to procure
them. Through this exhaustive process we were
able to obtain all relevant laws for all states
during the study period.
Legal Coding
For data abstraction, we created and fol-
lowed a detailed protocol to ensure consistency
between researchers and to permit others to
review and update our results. Two researchers
who were blinded to each other’s answers
independently coded each of 42 variables.
Each variable was coded for each state for each
month of the study period. Upon completion,
these answers were reviewed for divergence.
Where answers differed, a final answer was
reached by consensus of the research team. To
calculate interrater reliability, we randomly
selected 15 states by using a random number
generator. Rates of divergence for all variables
were recorded and calculated. The crude rate
of discordance was 0.92, with most differences
attributed to variations in interpretation of
ambiguous laws.
The abstraction form collected data on the
following 11 domains: general PMP opera-
tional characteristics, reporting provisions,
outlier identification, data sharing between
prescribers and dispensers, data access by re-
searchers, patient access to data, data sharing
with other PMPs, health professional access,
law enforcement access, oversight, and confi-
dentiality. The questions were developed via
a comprehensive review of the literature re-
garding PMPs as well as input from PMP
administrators, legal experts and epidemiologic
researchers.
The full data set, codebook, and protocol are
available at http://www.lawatlas.org.
RESULTS
In 1998, PMP legislation was present in only
13 states. By 2005 that number had nearly
doubled to 25, and by the end of 2011, 46
states had passed PMP legislation (although 1,
Wisconsin, had not yet enacted regulations
specifying many operational characteristics;
Figure 1). Although not analyzed as part of this
research, an additional 3 states (Arkansas,
Nebraska, and New Hampshire) passed autho-
rizing legislation in 2012---2013, bringing the
total number of states with enabling legislation
to 49 as of December 31, 2013. The charac-
teristics of these laws vary greatly among states,
and in many cases have changed significantly
over time.
Operating Agency
There was a pronounced shift in the types of
agencies that operate PMPs during the study
period. In 1998, 6 of 13 PMPs were operated
by, or in conjunction with, law enforcement
agencies. Of those, 4 were housed solely in law
enforcement or public safety agencies, while
a fifth was operated jointly by the state law-
enforcement agency and state pharmacy board,
and a sixth was operated by the state attorney
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general. Conversely, only 2 of the 33 PMPs
enacted between 1999 and 2011 are housed
in law enforcement agencies. New Jersey’s PMP
(authorized in 2009) is located in the Division
of Consumer Affairs in the Department of Law
and Public Safety, while Georgia’s (authorized
in 2011) is operated by the state Drugs and
Narcotics Agency “in consultation with mem-
bers of the Georgia Composite Medical Board”
(Ga. Code Ann. § 16-13-57).
Most recently enacted PMP laws place the
PMP in either the state health department or
a professional licensing agency, such as the
state medical or pharmacy board. By 2011
approximately 35% of PMPs were administra-
tively housed in health departments and 48%
in professional licensing authorities.
Data Submission requirements
Time period for reporting. During the study
period, states markedly increased the fre-
quency with which dispensers must report
information to the PMP. In 1998, only 1 state
required weekly reporting, and 8 (61.5%) re-
quired reports to be filed on a monthly basis.
The remaining 4 states (33%) permitted
reporting at a frequency less than monthly but
greater than weekly. Between 2005 and 2011
requirements that data be uploaded at least
weekly increased from 8.3% to 63% of states.
Still, in 2011, 6 states (13%) permitted data to
be uploaded at between weekly and monthly
frequencies, and 9 states (19.6%) continued to
permit monthly reporting. In 1998 and 2005
no states required same day reporting, but by
2011, 2 states (Oklahoma and North Dakota)
required reporting within 24 hours or less.
Schedules monitored. States, like the federal
government, classify controlled substances into
categories, or schedules, roughly based on their
level of safety and potential for abuse. Most
states follow the federal standard of 5 sched-
ules (denoted by Roman numerals) with lower
numbers indicating greater potential for harm.43
Common Schedule II drugs include strong opi-
oid analgesics such as oxycodone, methadone,
and morphine, as well as stimulants prescribed
for attention disorders like methylphenidate.
Schedule III includes hydrocodone combination
drugs, buprenorphine, anabolic steroids, and
some products containing codeine (the Food and
Drug Administration has recently recommended
that hydrocodone combination drugs be moved
to Schedule II). Schedules IV and V include
benzodiazepines, the neuropathic pain agent
pregabalin, and some sleep aids.
During the study period, states greatly in-
creased the number of schedules required to be
reported to PMPs (Figure 2). All state PMPs
required reporting of Schedule II drugs for the
entire study period. However, there was
a steady increase in the proportion of states
requiring Schedule III to be reported, increas-
ing from 38.5% in 1998 to 97.8% in 2011.
Schedule IV drugs followed a similar progres-
sion, increasing from 30.8% to 93.4%.
Reporting requirements for Schedule V drugs
saw an increase from 23.1% to 56.5% of states
during the study period. Several states also
require drugs not scheduled at the federal level
to be reported to the PMP. For example, in
2006 Ohio became the first state to modify its
law to explicitly require dispensers to report
tramadol, an opioid that was not federally
scheduled during the study period (in Novem-
ber 2013 the federal Drug Enforcement Ad-
ministration issued a Notice of Proposed Rule-
making adding tramadol to Schedule IV). By
2011, 6 other states had taken the same step.
Data Access
Proactive Access. PMPs can be either pro-
active or reactive; they can reactively respond
to external queries, or can proactively analyze
data for statistically outlying prescribers, dis-
pensers, or recipients of controlled substances.
Those PMPs that are permitted to proactively
analyze data are constrained by law in how
they may disseminate any findings.
In 1998, 4 of 13 states (30.8%) with PMP
laws were explicitly permitted to analyze sub-
mitted data, and 1 (Hawaii) was required to do
so. In 2005, 10 states (41.6%) permitted the
PMP to proactively analyze prescription data,
while 3 (12.5%) required such analysis. By
2011, 26 states (56.5%) explicitly permitted
the PMP to analyze collected data, of which 14
(30.4%) required such analysis. Of those 26
states, 10 required that individuals of concern
be reported to law enforcement, 13 required
reporting to the state professional licensing
agency, and 3 required reporting to the pre-
scriber or dispenser. Additionally, 8 states
permitted (but did not require) reporting to law
































Note. PMP = prescription monitoring program. The number of states with enabling legislation for prescription monitoring
programs grew steadily from 1998 to 2011.
FIGURE 1—Growth of States enacting prescription monitoring program legislation: United
States, 1998–2011.
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require reporting to the medical professional
and 5 to the state professional licensing agency.
Reactive Access. In 1998, 12 out of 13 PMPs
(92.3%) permitted law enforcement officers to
access prescription data of identified individ-
uals, while 61.5% permitted licensing boards
to do so. Less than one third of states (23.1%)
permitted physicians or pharmacists to access
patient-identifiable data. This had changed
dramatically by 2011, at which time 43 out of
46 states (93.5%) extended access to physi-
cians and 41 (89.1%) to pharmacists. Penn-
sylvania was the only state that did not permit
direct requests for patient data from any person
or entity during the study period.
No requirements that prescribers access the
PMP were in place in 1998 or 2005. By 2011,
5 states required some prescribers to access the
PMP in some circumstances. Delaware requires
prescribers to access the state PMP “when the
prescriber has a reasonable belief that the
patient may be seeking the controlled sub-
stance. . . for any reason other than the treat-
ment of an existing medical condition” (Del.
Code Ann. tit. 16 § 4798). Nevada employs the
same standard, with the addition that the pre-
scriber is required to access the PMP if the
patient is also new to the practitioner or the
practitioner has not prescribed a controlled
substance to the patient in the previous 12
months. Ohio requires physicians to access the
PMP if they suspect that a patient “may be
abusing or diverting drugs” or when they have
reason to believe that opioid therapy will be
required “on a protracted basis,” and at least
annually thereafter (Ohio Admin. Code §
4731-11-11). Louisiana’s requirement is lim-
ited to pain clinics, which are required to utilize
the PMP “as part of the clinics’ quality assur-
ance program” (La. Admin. Code tit. 48 § 7831).
Oklahoma’s requirement is limited to practi-
tioners who “prescribe, administer, or dispense”
methadone (Okla. Stat. Ann. tit. 16 § 2-302).
The nature of access provided to law en-
forcement officials has changed over time. In
1998, 3 states permitted at least some law
enforcement officials to access PMP data on
request, with no requirement that the request
be tied to an enumerated investigatory pur-
pose or court order. Six states (46.2%) re-
quired an active investigation to be underway
for some law enforcement to access identifi-
able PMP data. (Oklahoma appeared to permit
some officers to access the database with no
showing, while requiring that others be in-
volved in an investigation.) One state permitted
law enforcement access with a judicial sub-
poena or court order, and an additional 3
states permitted law enforcement access, but
the law did not clearly specify what standard
was employed.
In 2005 the same 3 states (12.5%) permit-
ted law enforcement access without any link to
an investigation, while 12 (50%) required an
active investigation, 3 required a subpoena, 2
(8.3%) required probable cause, and 3 re-
quired some other showing. By 2011, the
proportion of states permitting unfettered ac-
cess had dropped to 11% (5 states), while 22
(47.8%) permitted access pursuant to an active
investigation, 10 (21.7%) permitted access by
subpoena, and 5 imposed some other require-
ment. Nine (19.6%) required a showing of
probable cause. The law in 3 states did not appear
to permit law enforcement to access PMP data.
Some states permit access via multiple routes.
Data Safeguards. Most state PMP laws con-
tain penalties for illegal disclosure of PMP data,
and the penalties have generally increased over
time. In 1998, improper disclosure carried pos-
sible felony sanctions in 4 states (30.1%) and was
a misdemeanor in 3 others. Six states (46.2%)
had no explicit penalty for wrongful disclosure.
In 2005, 13 states (52%) imposed criminal
sanctions (6 at the felony level) while another 3
provided for other sanctions. Nine (37.5%) had
no explicit penalty. By 2011, 28 states (60.8%)
explicitly made improper disclosure of PMP data
a crime (in 18 it can be charged as a felony) while
14 provided for civil or professional penalties.
Only 8 states (17.3%) provided no explicit
penalty for wrongful disclosure.
PMP data retention laws have evolved over
time as well, but most states did not explicitly
address retention of identifiable PMP data as of
2011. In 1998 the laws in 3 states (23.1%)
directly addressed the question. Texas required
data to be purged in 1 year or less, while 2
(Hawaii and New York) required all identifying
information to be purged within 5 years. Two
additional states (Maine and New York) added
purging requirements by 2005. In 2011, 15
state PMP laws (32.6%) contained a require-
ment that data be de-identified or purged after
a period of time, with most requiring data to be
destroyed 5 years or less after submission.
DISCUSSION
PMP operational characteristics in most
























Note. PMP = prescription monitoring program. All prescription monitoring programs required data on Schedule II medicines to
be submitted during the entire study period. By 2011 nearly all states also required Schedules III and IV, but only
approximately half required reporting of Schedule V medications.
FIGURE 2—Requirements for medicines in selected federal drug schedules to be included in
state prescription monitoring programs: United States, 1998–2011.
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2011, and many attributes varied greatly
between states during the same time period.
We hope that the data reported here and
available online will be beneficial to re-
searchers attempting to determine the effects of
PMPs, and of particular PMP characteristics, on
opioid overdose and related health outcomes.
Some of these characteristics strike us as
particularly worthy of focus. Most experts agree
that if PMPs are to be effective, they must contain
(1) timely and complete records of (2) all relevant
data that can be (3) easily utilized by medical
professionals and licensing agencies to guide
medical decision-making and regulatory ac-
tion.44,45 This research identified positive trends
in all of these areas. We found large increases in
both the types of drugs required to be reported
to state PMPs and the types of requesters
permitted to access PMP data (as reported earlier,
the proportion of state PMPs that permit physi-
cians to directly access identifiable patient data
increased from 23.1% in 1998 to 93.5% in
2011). The data also reveal substantial decreases
in the amount of time permitted between when
reportable drugs are dispensed and the trans-
action is reported to the PMP.
However, there are many areas in which
PMPs fell short of expert recommendations.
For example, as of 2011 only 5 states required
prescribers to access the PMP, and those re-
quirements applied only to a subset of pre-
scribers in particular circumstances. Addition-
ally, while as of 2011 about two thirds of states
required that prescription data be reported to
the PMP in 1 week or less, in 9 states (16.6%)
transaction data were permitted to be as much
as a month old before being reported.
Some experts have suggested that individ-
uals identified by the PMP as receiving opioid
prescriptions at an elevated rate should be
referred for screening, counseling and addic-
tion treatment as appropriate.46,47 At the end
of 2011 no states required or explicitly per-
mitted such referrals. By contrast, 10 states
required PMPs to proactively report personally
identifiable suspicious prescription activity to
law enforcement, while another 8 permitted
such reports. Only 3 states required PMPs to
report patients with statistically outlying pre-
scription patterns to the patients’ physicians or
pharmacists. By focusing on such variations in
programs, researchers may be better able to
discover whether the empirical evidence
supports expert opinion regarding these char-
acteristics.
The interplay between law enforcement and
health professional data access seems to us
a particularly promising area for further re-
search. PMPs in nearly all states are tasked with
providing data to both the medical and law
enforcement communities. Law enforcement
and public health goals can be complemen-
tary,48---50 and PMPs may be capable of serving
both public health and law enforcement ends.
However, there is a long history of law en-
forcement interventions in the arena of illicit
drug control contributing to negative public
health outcomes,51---55 and the possibility that
some law enforcement uses of PMP data may
negatively affect health is not well addressed in
the existing literature.
For example, existing research typically does
not differentiate between either the mecha-
nisms by which law enforcement can access
PMP data or the types of persons targeted by
those data requests.44,56 The logic model by
which PMPs might be effective in reducing
opioid overdose when the data are utilized by
regulatory agencies and law enforcement offi-
cials to investigate grossly outlying prescribers,
while unproven, seems to us to be plausible.
Conversely, use of those data to facilitate the
arrest, prosecution, and incarceration of pa-
tients suffering the disease of addiction might
well lead to worse public health outcomes,
including increased overdose deaths.57---64 Re-
search into this question would be extremely
useful in guiding PMP law and policy.
The data presented here might also be useful
in attempting to determine if PMPs or some
PMP characteristics could have unintended
negative consequences such as reductions in
access to medically indicated pain treatment,
distrust between patients and providers, and
the diversion of prescription medication
abusers toward street drugs such as her-
oin.46,65---72 Finally, we note that, while PMPs
may be an important piece of the overdose
prevention puzzle, a marked reduction in opi-
oid overdose mortality will likely only be
accomplished with a multipronged approach
that addresses its many correlates.58,73---75
Limitations
This study examined state statutes and reg-
ulations explicitly regulating PMPs. It is possible
that areas of law that were not examined in
this research also impact PMP operation. This
study did not capture operational characteris-
tics that are not found in law, such as policy
decisions made by the state PMP agency, nor
did we attempt to discover whether the PMPs
were operating in conformity with the law.
Some relevant laws did not clearly address the
study questions and were interpreted using
general rules of statutory construction. Finally,
our analysis is based on the date the law
authorized the PMP to begin operations or
modify operational characteristics, which in
some cases may not match the date the PMP
actually did so.
Conclusions
PMPs have been suggested as important
tools in the effort to reduce the epidemic of
prescription drug overdose. Research to de-
termine whether and to what extent they are
effective in that goal has been stymied in part
because of a lack of a comprehensive database
of PMP operational characteristics. We have
created a transparent, replicable and updatable
compendium of PMP laws in effect from 1998
through 2011. A review of these laws found
that PMP laws changed dramatically over time,
and vary greatly between states. Research into
the effectiveness of PMPs should take these
variations into account. j
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